These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2206897)

  • 1. What treatment would you advise for a 1-year-old child with chronic renal failure who has been on aluminum hydroxide as a phosphate binder for 6 months and then develops epilepsy and is found to have a grossly raised plasma aluminum concentration?
    Andreoli SP; Chesney RW; Salusky IB; Sedman AB
    Pediatr Nephrol; 1990 Jul; 4(4):318. PubMed ID: 2206897
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk factors in aluminum toxicity in children with chronic renal failure.
    Santos F; Massie MD; Chan JC
    Nephron; 1986; 42(3):189-95. PubMed ID: 3511396
    [No Abstract]   [Full Text] [Related]  

  • 3. [The causes of aluminum cumulation and poisoning in patients with chronic kidney failure treated by hemodialysis on a regular program and the possibilities for therapy].
    Válek A; Sulková S; Laurinová Z
    Ter Arkh; 1991; 63(6):89-93. PubMed ID: 1948757
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphate-binding effects of sucralfate in patients with chronic renal failure.
    Roxe DM; Mistovich M; Barch DH
    Am J Kidney Dis; 1989 Mar; 13(3):194-9. PubMed ID: 2919600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aluminum, zinc and copper concentrations in plasma in chronic renal insufficiency.
    Zumkley H; Bertram HP; Lison A; Knoll O; Losse H
    Clin Nephrol; 1979 Jul; 12(1):18-21. PubMed ID: 477052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder.
    Malberti F; Surian M; Poggio F; Minoia C; Salvadeo A
    Am J Kidney Dis; 1988 Dec; 12(6):487-91. PubMed ID: 3143260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Iatrogenic aluminum osteopathy in a uremic infant].
    Koch H; Reich H; Franke D; Delling G
    Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing serum aluminum in CAPD patients.
    Montenegro J; Aguirre R; Saracho R; Moina I; Martínez I
    Clin Nephrol; 1998 Aug; 50(2):77-83. PubMed ID: 9725777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudohyperparathyroidism. Syndrome associated with aluminum intoxication in patients with renal failure.
    Sherrard DJ; Ott SM; Andress DL
    Am J Med; 1985 Jul; 79(1):127-30. PubMed ID: 4014298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a new phosphate binder in chronic renal insufficiency.
    Rutherford E; King S; Perry B; Blondin J; Finley T; Mason N; Sparks R; Slatopolsky E
    Kidney Int; 1980 Apr; 17(4):528-34. PubMed ID: 7392426
    [No Abstract]   [Full Text] [Related]  

  • 13. Prophylactic aluminium hydroxide and hyperaluminaemia in intensive care.
    Mackway-Jones K; Cove-Smith R; Lawler P
    Intensive Care Med; 1987; 13(4):293-4. PubMed ID: 3497185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperaluminaemia associated with oral citrate and aluminium hydroxide.
    Kirschbaum BB; Schoolwerth AC
    Hum Toxicol; 1989 Jan; 8(1):45-7. PubMed ID: 2714810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperaluminemia in renal failure: the influence of age and citrate intake.
    Bakir AA; Hryhorczuk DO; Ahmed S; Hessl SM; Levy PS; Spengler R; Dunea G
    Clin Nephrol; 1989 Jan; 31(1):40-4. PubMed ID: 2914409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aluminum-free intestinal phosphate binding.
    Schneider H; Kulbe KD; Weber H; Streicher E
    Contrib Nephrol; 1984; 38():32-6. PubMed ID: 6713898
    [No Abstract]   [Full Text] [Related]  

  • 17. [Aluminum poisoning by phosphate binders in kidney insufficiency].
    Fuchs C; Dorn D; Doht B; Freytag E; Fuchs CA; Henning HV; Scheler F
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1313-5. PubMed ID: 611842
    [No Abstract]   [Full Text] [Related]  

  • 18. Bowel obstruction occurring in a child during treatment with aluminum hydroxide gel.
    Hurley JK
    J Pediatr; 1978 Apr; 92(4):592-3. PubMed ID: 633020
    [No Abstract]   [Full Text] [Related]  

  • 19. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure.
    Andreoli SP; Dunson JW; Bergstein JM
    Am J Kidney Dis; 1987 Mar; 9(3):206-10. PubMed ID: 3826069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persisting aluminium-related bone disease after cadaveric renal transplantation.
    Nicholas JC; Dawes PT; Davies SJ; Freemont AJ
    Nephrol Dial Transplant; 1999 Jan; 14(1):202-4. PubMed ID: 10052510
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.